Loading…
Predictive Model for Plasma Concentration-Versus-Time Profiles of Investigational Anticancer Drugs in Patientsi
We report a model that provides a strong correlation between mouse toxicity data [mouse lethal dose 10% (LD10)] and human plasma concentration-versus-time (CXT) data for 22 commonly used anticancer agents. Mouse toxicity data (LD10) from two dosing schedules, daily times one and daily times seven, w...
Saved in:
| Published in: | JNCI : Journal of the National Cancer Institute 1988-08, Vol.80 (11), p.815-819 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c190t-825d4382522c69e8021818c3a8b07d2c095e4cd5c193fd77e863bb6cf706382b3 |
|---|---|
| cites | |
| container_end_page | 819 |
| container_issue | 11 |
| container_start_page | 815 |
| container_title | JNCI : Journal of the National Cancer Institute |
| container_volume | 80 |
| creator | Davis, Lisa E. Alberts, David S. Plezia, Patricia M. Roe, Denise J. Griswold, Daniel P. |
| description | We report a model that provides a strong correlation between mouse toxicity data [mouse lethal dose 10% (LD10)] and human plasma concentration-versus-time (CXT) data for 22 commonly used anticancer agents. Mouse toxicity data (LD10) from two dosing schedules, daily times one and daily times seven, were evaluated for the two mouse strains BDF/1 and Swiss. Data from BDF/1 mice were selected for analysis because they were more abundant. Strong correlations were found between LD10 and human plasma CXT data for both daily times one and daily times seven dosing schedules—In (CXT) = −1.6504 + [0.8408 × In (LD10)], r = .84, P < .0001, and In (CXT) = −0.0754 + [0.8954 × In (LD10)], r = .90, P < .0001, respectively. These correlations may serve as useful models to predict the maximally tolerated dose of an investigational anticancer agent prior to entry into clinical trials and to assist in the selection of clinically relevant in vitro CXTs for new-agent screening against human tumors. |
| doi_str_mv | 10.1093/jnci/80.11.815 |
| format | article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_jnci_80_11_815</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_HXZ_K95ZQPN8_4</sourcerecordid><originalsourceid>FETCH-LOGICAL-c190t-825d4382522c69e8021818c3a8b07d2c095e4cd5c193fd77e863bb6cf706382b3</originalsourceid><addsrcrecordid>eNo9kEtPwzAQhC0EEqVw5ew_4NaPOHaOVXm0okCQCkK9WI7jVC5pjOy0gn-PSxF72NVo55vDAHBN8Ijggo03nXFjmQQZScJPwIBkOUaUYH4KBhhTgaQU2Tm4iHGD0xQ0GwBfBls707u9hY--ti1sfIBlq-NWw6nvjO36oHvnO_RmQ9xFtHRbC8vgG9faCH0D593ext6tf126hZOud0YnMsCbsFtH6DpYpmdKiu4SnDW6jfbq7w7B693tcjpDi-f7-XSyQIYUuEeS8jpjaVNq8sJKTIkk0jAtKyxqanDBbWZqntysqYWwMmdVlZtG4DxhFRuC0THXBB9jsI36DG6rw7ciWB3qUoe6lEyCqFRXAtARcLG3X_9uHT5ULpjgava-Ug8FX72UT1Jl7AeCcm8R</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Predictive Model for Plasma Concentration-Versus-Time Profiles of Investigational Anticancer Drugs in Patientsi</title><source>Oxford University Press Archive</source><creator>Davis, Lisa E. ; Alberts, David S. ; Plezia, Patricia M. ; Roe, Denise J. ; Griswold, Daniel P.</creator><creatorcontrib>Davis, Lisa E. ; Alberts, David S. ; Plezia, Patricia M. ; Roe, Denise J. ; Griswold, Daniel P.</creatorcontrib><description>We report a model that provides a strong correlation between mouse toxicity data [mouse lethal dose 10% (LD10)] and human plasma concentration-versus-time (CXT) data for 22 commonly used anticancer agents. Mouse toxicity data (LD10) from two dosing schedules, daily times one and daily times seven, were evaluated for the two mouse strains BDF/1 and Swiss. Data from BDF/1 mice were selected for analysis because they were more abundant. Strong correlations were found between LD10 and human plasma CXT data for both daily times one and daily times seven dosing schedules—In (CXT) = −1.6504 + [0.8408 × In (LD10)], r = .84, P < .0001, and In (CXT) = −0.0754 + [0.8954 × In (LD10)], r = .90, P < .0001, respectively. These correlations may serve as useful models to predict the maximally tolerated dose of an investigational anticancer agent prior to entry into clinical trials and to assist in the selection of clinically relevant in vitro CXTs for new-agent screening against human tumors.</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/80.11.815</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>JNCI : Journal of the National Cancer Institute, 1988-08, Vol.80 (11), p.815-819</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c190t-825d4382522c69e8021818c3a8b07d2c095e4cd5c193fd77e863bb6cf706382b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Davis, Lisa E.</creatorcontrib><creatorcontrib>Alberts, David S.</creatorcontrib><creatorcontrib>Plezia, Patricia M.</creatorcontrib><creatorcontrib>Roe, Denise J.</creatorcontrib><creatorcontrib>Griswold, Daniel P.</creatorcontrib><title>Predictive Model for Plasma Concentration-Versus-Time Profiles of Investigational Anticancer Drugs in Patientsi</title><title>JNCI : Journal of the National Cancer Institute</title><description>We report a model that provides a strong correlation between mouse toxicity data [mouse lethal dose 10% (LD10)] and human plasma concentration-versus-time (CXT) data for 22 commonly used anticancer agents. Mouse toxicity data (LD10) from two dosing schedules, daily times one and daily times seven, were evaluated for the two mouse strains BDF/1 and Swiss. Data from BDF/1 mice were selected for analysis because they were more abundant. Strong correlations were found between LD10 and human plasma CXT data for both daily times one and daily times seven dosing schedules—In (CXT) = −1.6504 + [0.8408 × In (LD10)], r = .84, P < .0001, and In (CXT) = −0.0754 + [0.8954 × In (LD10)], r = .90, P < .0001, respectively. These correlations may serve as useful models to predict the maximally tolerated dose of an investigational anticancer agent prior to entry into clinical trials and to assist in the selection of clinically relevant in vitro CXTs for new-agent screening against human tumors.</description><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><recordid>eNo9kEtPwzAQhC0EEqVw5ew_4NaPOHaOVXm0okCQCkK9WI7jVC5pjOy0gn-PSxF72NVo55vDAHBN8Ijggo03nXFjmQQZScJPwIBkOUaUYH4KBhhTgaQU2Tm4iHGD0xQ0GwBfBls707u9hY--ti1sfIBlq-NWw6nvjO36oHvnO_RmQ9xFtHRbC8vgG9faCH0D593ext6tf126hZOud0YnMsCbsFtH6DpYpmdKiu4SnDW6jfbq7w7B693tcjpDi-f7-XSyQIYUuEeS8jpjaVNq8sJKTIkk0jAtKyxqanDBbWZqntysqYWwMmdVlZtG4DxhFRuC0THXBB9jsI36DG6rw7ciWB3qUoe6lEyCqFRXAtARcLG3X_9uHT5ULpjgava-Ug8FX72UT1Jl7AeCcm8R</recordid><startdate>19880803</startdate><enddate>19880803</enddate><creator>Davis, Lisa E.</creator><creator>Alberts, David S.</creator><creator>Plezia, Patricia M.</creator><creator>Roe, Denise J.</creator><creator>Griswold, Daniel P.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19880803</creationdate><title>Predictive Model for Plasma Concentration-Versus-Time Profiles of Investigational Anticancer Drugs in Patientsi</title><author>Davis, Lisa E. ; Alberts, David S. ; Plezia, Patricia M. ; Roe, Denise J. ; Griswold, Daniel P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c190t-825d4382522c69e8021818c3a8b07d2c095e4cd5c193fd77e863bb6cf706382b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Davis, Lisa E.</creatorcontrib><creatorcontrib>Alberts, David S.</creatorcontrib><creatorcontrib>Plezia, Patricia M.</creatorcontrib><creatorcontrib>Roe, Denise J.</creatorcontrib><creatorcontrib>Griswold, Daniel P.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Davis, Lisa E.</au><au>Alberts, David S.</au><au>Plezia, Patricia M.</au><au>Roe, Denise J.</au><au>Griswold, Daniel P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive Model for Plasma Concentration-Versus-Time Profiles of Investigational Anticancer Drugs in Patientsi</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><date>1988-08-03</date><risdate>1988</risdate><volume>80</volume><issue>11</issue><spage>815</spage><epage>819</epage><pages>815-819</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><abstract>We report a model that provides a strong correlation between mouse toxicity data [mouse lethal dose 10% (LD10)] and human plasma concentration-versus-time (CXT) data for 22 commonly used anticancer agents. Mouse toxicity data (LD10) from two dosing schedules, daily times one and daily times seven, were evaluated for the two mouse strains BDF/1 and Swiss. Data from BDF/1 mice were selected for analysis because they were more abundant. Strong correlations were found between LD10 and human plasma CXT data for both daily times one and daily times seven dosing schedules—In (CXT) = −1.6504 + [0.8408 × In (LD10)], r = .84, P < .0001, and In (CXT) = −0.0754 + [0.8954 × In (LD10)], r = .90, P < .0001, respectively. These correlations may serve as useful models to predict the maximally tolerated dose of an investigational anticancer agent prior to entry into clinical trials and to assist in the selection of clinically relevant in vitro CXTs for new-agent screening against human tumors.</abstract><pub>Oxford University Press</pub><doi>10.1093/jnci/80.11.815</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-8874 |
| ispartof | JNCI : Journal of the National Cancer Institute, 1988-08, Vol.80 (11), p.815-819 |
| issn | 0027-8874 1460-2105 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_jnci_80_11_815 |
| source | Oxford University Press Archive |
| title | Predictive Model for Plasma Concentration-Versus-Time Profiles of Investigational Anticancer Drugs in Patientsi |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A21%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20Model%20for%20Plasma%20Concentration-Versus-Time%20Profiles%20of%20Investigational%20Anticancer%20Drugs%20in%20Patientsi&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Davis,%20Lisa%20E.&rft.date=1988-08-03&rft.volume=80&rft.issue=11&rft.spage=815&rft.epage=819&rft.pages=815-819&rft.issn=0027-8874&rft.eissn=1460-2105&rft_id=info:doi/10.1093/jnci/80.11.815&rft_dat=%3Cistex_cross%3Eark_67375_HXZ_K95ZQPN8_4%3C/istex_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c190t-825d4382522c69e8021818c3a8b07d2c095e4cd5c193fd77e863bb6cf706382b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |